The chronic hepatitis B market is primarily driven by the increasing incidence of high-risk behaviors such as unprotected sexual intercourse with an infected partner, sharing needles or other drug paraphernalia, and exposure to infected blood or body fluids.

1. Chronic Hepatitis B
Market Research
Report 2023-2033

2. ABOUT IMARC
2
International Market Analysis Research and Consulting Group is a
leading adviser on management strategy and market research
worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific,
economic and technological developments for business leaders in
pharmaceutical, industrial, and high technology organizations.
Market forecasts and industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel and tourism,
nanotechnology and novel processing methods are at the top of
the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into
the dynamics of companies and markets with close cooperation at
all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient
organizations, and secure lasting results.

3. Report Description and Highlights
Chronic Hepatitis B Market 2023-2033
The newly published report by IMARC Group, titled ”Chronic Hepatitis B Market: Epidemiology, Industry Trends, Share, Size, Growth,
Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the chronic hepatitis B market. The report provides an
overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease
overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent
advancements in the seven major markets (7MM). The report also highlights key segments and market drivers, as well as challenges
faced by industry players.
Request a Sample Report: https://www.imarcgroup.com/chronic-hepatitis-b-market/requestsample
3

4. Report Description and Highlights
What is Chronic Hepatitis B?
Chronic hepatitis B refers to a long-term liver ailment caused by the hepatitis B virus (HBV). Its symptoms include fatigue, nausea,
abdominal discomfort, loss of appetite, and jaundice, which causes yellowing of the skin and eyes. In severe cases, patients may experience
liver disease, resulting in symptoms such as fluid retention, easy bruising or bleeding, and confusion.
Chronic hepatitis B is diagnosed by a comprehensive approach combining blood tests and clinical evaluation. In addition, serological tests
are utilized to detect specific markers of HBV infection. Additionally, various imaging studies, such as ultrasound and liver biopsy, are also
performed to assess liver structure and determine the extent of liver damage.
4

5. Report Description and Highlights
What are the key drivers and trends in the Chronic Hepatitis B market?
The chronic hepatitis B market is primarily driven by the increasing incidence of high-risk behaviors such as unprotected sexual intercourse
with an infected partner, sharing needles or other drug paraphernalia, and exposure to infected blood or body fluids. Furthermore, the
widespread adoption of various antiviral agents, including nucleotide/nucleoside analogs and pegylated interferon-alpha (PEG-IFN), to
suppress viral replication, reduce liver inflammation, and slow down disease progression is contributing to the market growth.
Moreover, the growing demand for liver fibrosis assessment methods, such as transient elastography and serum biomarkers, which offers a
safer and less invasive alternative to liver biopsy, thus reducing patient discomfort and minimizing the risks associated with invasive
procedures, is supporting the market growth. Additionally, the emerging popularity of immune modulation strategies, which stimulate the
immune system to achieve sustained viral suppression and serological response, including hepatitis B surface antigen (HBsAg) loss, is
positively influencing the market growth.
5

6. Report Description and Highlights
What is included in the report segmentation?
The report covers the following aspects:
Report Period:
• Base Year: 2022
• Historical Period: 2017-2022
• Market Forecast: 2023-2033
Countries Included:
• United States
• Germany
• France
6

7. Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Chronic Hepatitis B market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Chronic Hepatitis B market
• Reimbursement scenario in the market
• In-market and pipeline drugs
7

8. Report Description and Highlights
In-Market Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Regulatory Status
View Report TOC, Figures and Tables: https://www.imarcgroup.com/chronic-hepatitis-b-market
8

9. Key Questions Answered in the Report
1. How has the Chronic Hepatitis B market performed so far and how will it perform in the coming years?
2. What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
3. What was the country-wise size of the Chronic Hepatitis B market across the seven major markets in 2022 and what will it look like in
2033?
4. What is the growth rate of the Chronic Hepatitis B market across the seven major markets and what will be the expected growth over
the next ten years?
5. What are the key unmet needs in the market?
9

10. Table of
Contents

11. Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
11

12. Table of Contents
4 Chronic Hepatitis B - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
4.4 Market Overview (2017-2022) and Forecast (2023-2033)
4.5 Competitive Intelligence
5 Chronic Hepatitis B - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/chronic-hepatitis-b-
market/toc
12

13. Partial List Of Our Clients
13

14. OUR CLIENTS
14

15. Disclaimer
15
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis
Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or
in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including
photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information
and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting
makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts
no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and
Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.